Patrick Arsenault
Senior Director, Lead Discovery Triana Biomedicines
Patrick has been involved in E3 ligase biology and degrader discovery for the better part of the last 15 years with various roles in early stage discovery supporting assay development, degrader characterization and target identification. He has led teams supporting in vitro pharmacology, biophysics and cell biology for both bivalent and monovalent degrader discovery programs across neuroscience, immunology, and oncology indications.
Seminars
Identifying early molecular glue hits requires sensitive assays, as standard binding or inhibition tests often fail to capture functional activity. Capturing hits requires carefully designed biochemical, cell-based, and proteomics assays that reflect ternary complex formation and target degradation. While ternary complexes remain central to glue discovery, recent insights suggest that maximal stability is not always optimal for degradation. This workshop will explore strategies for implementing tiered
screening cascades, validating hits across multiple contexts, and considering target expression, E3 ligase availability, and multi-protein complexes to improve translation into downstream studies.
This workshop will gather experts to discuss:
- Capturing relevant hits using biochemical, cell-based, and proteomics assays detects transient PPIs and ternary complexes effectively
- Prioritizing meaningful candidates with tiered screening cascades to confirm degradation, selectivity, and mechanism while reducing false positives
- Accounting for biological context by considering target expression, E3 ligase availability, and multi-protein complexes and the dynamic nature of ternary interactions to improve translation in vivo
This session is designed for chemists, biologists, and translational scientists looking to optimize screening cascades and improve the reliability of early-stage hit selection.
